What is Amiodarone?
Amiodarone is a potent class III antiarrhythmic used to treat atrial and ventricular tachyarrhythmias, especially when other therapies are ineffective or contraindicated. Because it contains iodine and has a long half-life with tissue accumulation, chronic therapy requires monitoring for thyroid toxicity, along with pulmonary, hepatic, and ocular toxicity.
What is the mechanism of action of Amiodarone?
Amiodarone extends beyond potassium blockade to include sodium, calcium, and beta-adrenergic inhibition. The combined effect slows phase 0, prolongs phase 3, and reduces adrenergic drive. These changes prolong the action potential and refractory periods.
Amiodarone slows sinus and AV nodal conduction and delays repolarization. These effects can prolong the QT interval and, rarely, contribute to torsades de pointes, especially with other QT-prolonging drugs or predisposing factors (e.g., bradycardia/electrolyte disturbance).
What are the clinical uses (Indications) of Amiodarone?
Amiodarone is used for rhythm control in both atrial fibrillation and flutter when patients remain symptomatic despite rate-control drugs. It stabilizes ventricular tachycardia and ventricular fibrillation after defibrillation fails in cases of structural heart disease. Amiodarone may also be used as an adjunct to cardioversion in selected patients. Atrial fibrillation with pre-excitation should be managed in consultation with cardiology or electrophysiology and requires careful agent selection.
Loading regimens often use 800 to 1,600 mg daily, split over the first week. Maintenance doses typically range from 200 to 400 mg daily once levels stabilize.
What are the adverse effects and contraindications of Amiodarone?
The adverse effects of amiodarone include pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, and corneal deposits, requiring vigilant surveillance. Bradycardia, sinus-node dysfunction, and optic neuropathy also appear after weeks to months of therapy. Many monitoring protocols recommend baseline chest imaging, thyroid and liver testing, and pulmonary assessment when starting long-term therapy.
The adverse effects profile also encompasses photosensitivity, neuropathy, and accumulation in adipose tissue, prolonging the elimination half-life. In thyroid storm, atrial fibrillation often responds poorly to cardioversion until thyroid hormone excess is controlled. The contraindications of amiodarone include severe sinus-node disease, advanced atrioventricular block without a pacemaker, and hypersensitivity to amiodarone. Patients should avoid grapefruit and its juice, which can increase amiodarone levels and adverse effects, and clinicians should look out for major drug interactions (e.g., warfarin, digoxin, certain statins).
What are some examples of Amiodarone?
Examples of Amiodarone include the oral tablets Cordarone and Pacerone plus intravenous solution for emergent settings. Emergency departments often start with 150 mg over ten minutes, then continue with 1 mg per minute for six hours, followed by 0.5 mg per minute for 18 hours.
Inpatients receive high oral loading (600 to 800 mg daily) for one to two weeks to saturate tissues before decreasing to maintenance. Pharmacies supply premixed infusions, so teams must verify compatibility with other intravenous drugs.
What are the most important facts to know about Amiodarone?
- Amiodarone is a potent class III antiarrhythmic reserved for symptomatic, refractory atrial fibrillation and ventricular arrhythmias.
- The mechanism of action of amiodarone includes sodium, calcium, and potassium blockade plus beta inhibition, which lengthens refractory periods.
- Indications include cardioversion support, chronic rhythm control, and life-saving therapy after ventricular fibrillation that resists shocks.
- The adverse effects of amiodarone demand thyroid, pulmonary, hepatic, and ocular surveillance to balance efficacy and toxicity.
- Avoid use in severe sinus-node disease, advanced AV block without pacing, and hypersensitivity to amiodarone, which are contraindications of amiodarone use.
References
- Hoofnagle, J. H. (2026, February 6). Amiodarone. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548109/
- Macfarlane, K., Russell, M., Paterson, K., & Maroni, K. (2025). Amiodarone drug specific monitoring document. Medicines Policy and Guidance Team. https://www.rightdecisions.scot.nhs.uk/media/015csx3y/amiodarone-drug-specific-monitoring-document.pdf
- Scaramozzino, M. U., Sr., Sapone, G., Plastina, U. R., & Nucara, M. (2023). Amiodarone-induced lung toxicity: A case initially not correctly framed. Cureus, 15(3), Article e36818. https://doi.org/10.7759/cureus.36818
- Șorodoc, V., Indrei, L., Dobroghii, C., Asaftei, A., Ceasovschih, A., Constantin, M., Lionte, C., Morărașu, B. C., Diaconu, A.-D., & Șorodoc, L. (2024). Amiodarone therapy: Updated practical insights. Journal of Clinical Medicine, 13(20), Article 6094. https://doi.org/10.3390/jcm13206094
- You, H.-S., Yoon, J. H., Cho, B. S., Choi, Y.-D., Kim, Y. H., Choi, W., Kang, H.-C., & Choi, S. K. (2022). Amiodarone-induced multi-systemic toxicity involving the liver, lungs, thyroid, and eyes: A case report. Frontiers in Cardiovascular Medicine, 9, Article 839441. https://doi.org/10.3389/fcvm.2022.839441